News related to
next

Mr Munafò joined Allianz Trade in 2015 as part of the Multinationals team and has spent over a decade shaping the company’s commercial strategy across four regions. Rising through key account management roles spanning MMEA, APAC, and Northern Europe – including his appointment as Regional Account Director for Northern Europe in 2021 – he was named Group Head of Broker Management and Partnerships in 2025, where he was responsible for defining and executing Allianz Trade’s global commercial and distribution strategy and strengthening broker partnerships across multiple regions. Mr Munafò holds an MBA from POLIMI Graduate School of Management (Politecnico di Milano) and a degree in Law from Università Bocconi with a major in Public Sector and Law.

On this appointment, Rodrigo Jimenez, Regional CEO at Allianz Trade in Asia Pacific, says: “Over the past decade, Scott has built extensive experience across various regions, demonstrating a strong track record in growing commercial portfolios, building strategic partnerships, and maintaining exceptional customer retention. His international experience, commercial leadership, and deep understanding of our business make him exceptionally well positioned to lead our China operations. I am confident that, together with the local management team, Scott will successfully drive our growth ambitions and deliver continued success in this important and fast-growing market.”

Mr Munafò remarks: “Allianz Trade has been part of China’s trade story for nearly two decades – built on the strength of our team, our partners, and our customers who have trusted us through every cycle. I am honoured to be entrusted with what so many have built together. My commitment is simple: to keep listening, to keep creating lasting value and to ensure the next chapter sets a new standard.”
Hashtag: #allianztrade #tradecreditinsurance

https://www.allianz-trade.com/en_HK.html
https://www.linkedin.com/company/allianz-trade-apac/

The issuer is solely responsible for the content of this announcement.

About Allianz Trade

Allianz Trade is the global leader in trade credit insurance and a recognized specialist in the areas of surety, collections, structured trade credit and political risk. Our proprietary intelligence network is based on instant access to data of 289 million corporates. We give companies the confidence to trade by securing their payments. We compensate your company in the event of a bad debt, but more importantly, we help you avoid bad debt in the first place. Whenever we provide trade credit insurance or other finance solutions, our priority is predictive protection. But, when the unexpected arrives, our AA credit rating means we have the resources, backed by Allianz to provide compensation to maintain your business. Headquartered in Paris, Allianz Trade is present in over 40 countries with 5,900 employees. In 2025, our consolidated turnover was EUR4 billion and insured global business transactions represented EUR1,400 billion in exposure. For more information, please visit allianz-trade.com.

Over the three-day event, more than 60 distinguished leaders and professionals from the technology, entertainment and creative sectors in Hong Kong, the Chinese Mainland and around the world will discuss how AI, immersive technologies and cutting-edge innovations are reshaping content creation and entertainment experiences. As AI continues to lower the barriers to creation, the content industry is rapidly evolving from content production toward the development of the IP economy. This year’s forum will focus on how AI empowers creators and enterprises to build globally competitive original intellectual properties (IPs), while examining how Cyberport’s AI infrastructure, innovation ecosystem and international network can help transform innovative ideas into commercialised products, brands and globally recognised IPs, further strengthening Hong Kong’s position as a leading digital entertainment and IP innovation hub in Asia.

Dr Rocky Cheng, Chief Executive Officer of Cyberport, said: “Artificial intelligence is reshaping the cultural and creative industries, opening up unprecedented opportunities for creators, businesses and society. DELF 2026 brings together technology, creativity and business to foster cross-sector collaboration, advance original content creation, support IP incubation and accelerate commercial applications. Leveraging its AI infrastructure, industry ecosystem and global partnership network, Cyberport will continue to support innovative enterprises and original IP creators in seizing the opportunities of the AI era and expanding into international markets.”

Today, Cyberport also hosted a special panel discussion titled “From AI Creation to Global IP: New Opportunities for the Entertainment Industry,” bringing together industry experts to explore emerging opportunities in content creation, IP incubation and commercialisation in the age of AI. Moderated by Ir Eric Chan, Chief Public Mission Officer of Cyberport, the discussion featured Mr Frankie Tam, Creative Director of Ultra Instinct Limited; Ms Polly Yeung, Chief Executive Officer of Gudo Inc.; and Ms Louie Cheng, Director of AI Education and OPC Entrepreneurship Incubation at FizzDragon. Panellists agreed that AI is not only significantly enhancing content creation efficiency but is also accelerating the transition of the content industry into the era of the IP economy, creating broader commercial and international development opportunities for Hong Kong’s original IPs.

Ir Eric Chan, Chief Public Mission Officer of Cyberport, said: “AI is unlocking unprecedented creative possibilities and injecting fresh momentum into Hong Kong’s cultural and creative industries. As the industry enters a new phase of transformation, our focus should go beyond encouraging the creation of original content. We must also help promising IP develop long-term value, progressing from creative ideas to practical applications, and from individual works to recognised brands. Cyberport will continue to advance its public mission by connecting technology, creativity, talent and industry resources, empowering more local creators and enterprises to harness AI and turn Hong Kong’s creativity into market-ready outcomes with international potential.”

Over the three days, the forum will feature discussions on a wide range of topics, including AI collaboration, IP ecosystem development, the cultural and creative economy, smart cities, and future living. Speakers and representatives from organisations such as the University of Southern California (USC), The Hong Kong Academy for Performing Arts, TVB Plus, GGWP, Mei Ah Entertainment, and Xi’an XR Film Industry Base will share insights on how AI is driving innovation, commercialisation and globalisation across the creative industries.

In addition, the interactive experience zone will feature four themed areas and more than 35 experiential activities, showcasing diverse digital entertainment and smart living scenarios powered by AI, immersive technologies and other advanced innovations.

The four themed zones include:

• Arts & Culture – featuring the immersive interactive art exhibition Another World: RADIANCE, Cyberport’s original immersive cultural exhibition The Reveries of Ancient Egypt, Hong Kong’s first XR 6D experience Harbour Dreams: Hong Kong XR Adventure, and the complete VR experience Versailles: The Lost Gardens of the Sun King VR experience.
• Digital Entertainment – showcasing innovative projects including Nikopicto’s interactive skateboard experience SkateAway Circus, TVB Music Money Monster System, and the FizzDragon AI Short Drama Creation Platform.
• Smart Living & Business – featuring products such as Genesis One’s 3D & AI Smart Fashion Platform, allowing visitors to experience how technology is transforming everyday life.
• Robotics & Drones – presenting consumer robotics innovations such as combat robots and AI interactive smart vehicles developed by Jin Technology, alongside the “Charting the Future: eVTOL Inaugural Test Flight,” highlighting the latest developments in interactive technology, the low-altitude economy and smart mobility.

To encourage visitors to explore the diverse digital entertainment experiences, DELF 2026 will launch a special “Play-to-Earn” campaign that combines gamification and rewards. Participants can collect stamps by completing designated tasks across the four themed zones and redeem gifts, while those who complete all challenges will have a chance to receive limited-edition merchandise from the Hong Kong original animation IP Another Worlds.

The event will also feature AI interactive workshops under the Cyberport Academy: DELF 2026 – AI Cultural & Creative Micro-Academy, where participants can learn creative skills such as concept art design and video production. In addition, the event will feature a special movie screening programme showcasing a Mars-themed AIGC sci-fi short drama from Singapore, selected works from the 3rd AI-assisted animation production support scheme, and 2nd HKUST AI Film Festival. Complemented by a live performance from popular K-pop band XODIAC and an indoor drone cirque, the programme will deliver an immersive experience that brings together artificial intelligence, digital entertainment and creative technology.

For more information about DELF 2026 and the speaker lineup, please visit: https://delf.cyberport.hk.

Please click HERE to download the high-resolution press photos.

Hashtag: #DELF #Cyberport

The issuer is solely responsible for the content of this announcement.

About Hong Kong Cyberport

Wholly owned by the Hong Kong Special Administrative Region (HKSAR) Government, Cyberport is Hong Kong’s digital tech hub and AI accelerator, with a vision to empower industry digitalisation and intelligent transformation, to promote digital economy and AI development, and to foster Hong Kong to be an international AI, innovation and technology (I&T) hub. Cyberport gathers over 2,400 companies, including 29 listed companies and 10 unicorns. One-third of onsite companies’ founders come from 28 countries and regions, while Cyberport companies have expanded to over 35 global markets.

Cyberport, with Hong Kong’s largest AI Supercomputing Centre and AI Lab as the engine, has been building the AI ecosystem with industry-leading AI companies and over 500 AI and data science start-ups. Through development of tech clusters, namely AI, data science, blockchain and cybersecurity, Cyberport empowers industries across smart city and government, banking and finance, digital entertainment, culture and tourism, healthcare, education and training, property management, construction, transportation and logistics, green environment and more, while hosting Hong Kong’s largest FinTech community. Commissioned by the HKSAR Government, Cyberport has implemented proof-of-concept and sandbox schemes, subsidisation for digital tech adoption, industry tech training and start-up incubation, to drive technology R&D, translation and commercialisation, thus propelling digital transformation and intelligent upgrade across industry and society.

Also as “State-level Scientific and Technological Enterprise Incubator” and Hong Kong’s key incubator, Cyberport supports entrepreneurs with funding and office space, extensive networks of enterprises, investors, technology corporations and professional services for business growth and expansion to Chinese Mainland and overseas markets, all-round facilitation for landing in Hong Kong, talent attraction and cultivation, ready as a launchpad to take start-ups in any stages of development to the next level.

For more information, please visit https://www.cyberport.hk/en.

Nationwide #AreYourKidneysOK+? initiative expands access to subsidised blood screening, public education, and pharmacist support for 12,550 Malaysians.

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 19 August 2026 – As chronic conditions such as diabetes, cardiovascular disease and chronic kidney disease continue to affect Malaysians, early detection is becoming increasingly important in reducing complications and improving long-term health outcomes.

These conditions are closely interconnected across the Cardio-Kidney-Metabolic spectrum, meaning that a problem affecting one area of health may also increase the risks to other parts of the body. However, many individuals may not recognise these risks until their condition has progressed or complications have developed.

One such complication is hyperkalemia, a condition characterised by elevated potassium levels in the blood. Hyperkalemia is more common among people living with chronic kidney disease because impaired kidneys may have lower ability to remove excess potassium from the body. As the condition may not always present noticeable warning signs, it remains under-recognised by the public and may lead to serious complications affecting the heart’s rhythm if not appropriately identified and managed.

Recognising the need to strengthen early detection and public awareness across the Cardio-Kidney-Metabolic (CKM) spectrum, Alpro Group, in collaboration with AstraZeneca Malaysia, announced the launch of #AreYourKidneysOK+?, a nationwide awareness campaign dedicated to encourage early detection, promoting kidney health, and raising awareness of hyperkalemia.

This nationwide initiative aims to empower Malaysians to better understand the connection between their heart, kidney and metabolic health, while bringing greater attention to hyperkalemia as an often-overlooked complication associated with chronic kidney disease.

At the heart of the campaign is a subsidised blood screening programme aimed at encouraging more Malaysians to take an earlier and more proactive approach to their health. Eligible individuals will receive subsidy on selected blood test packages, to reduce financial barriers in screening and to support the earlier identification of potential Cardio-Kidney-Metabolic and health risks.

The campaign aims to reach 12,550 individuals across Malaysia, a shared commitment by Alpro Group and AstraZeneca Malaysia to turn public health awareness into meaningful action.

Beyond providing financial support for screening, the campaign creates a more accessible pathway for Malaysians to learn about their potential health risks, undergo appropriate screening and speak to their healthcare professionals about the next steps they may need to undertake.

To extend the campaign’s reach beyond physical pharmacy locations, the initiative is supported by a dedicated digital health education platform containing trusted and easy-to-understand information about hyperkalemia, including its causes, risk factors, possible warning signs and relationship with chronic kidney disease.

The platform serves as a public health resource that Malaysians can access at any time, helping individuals and caregivers better understand hyperkalemia and prepare for more informed conversations with pharmacists, doctors and other healthcare professionals.

Through Alpro Group’s community healthcare network, members of the public will also have greater access to pharmacist support and guidance. Alpro pharmacists can help individuals better understand the importance of screening, recognise relevant risk factors and seek appropriate medical assessment or follow-up when necessary.

“Many chronic health risks develop quietly and may only be discovered after complications have occurred. Through this campaign, we want to make preventive healthcare more accessible by connecting public education, affordable screening and professional healthcare support. By targeting 12,550 Malaysians, we hope to encourage more people to take an earlier and more proactive step towards understanding their heart, kidney and metabolic health,” said Dr. Ng Ming Lee, Medical Director of Alpro Clinic.

“As chronic kidney disease remains a significant public health challenge in Malaysia, this collaboration reflects a shared commitment across the healthcare ecosystem to strengthen public awareness of kidney health and bring health education closer to the public. Through Alpro Group’s nationwide network, we aim to help more Malaysians learn about relevant risk factors and have informed conversations with healthcare professionals to support appropriate assessment and follow-up,” said Dr. Svetlana Yanchuk, Country President, AstraZeneca Malaysia.

Through this collaboration, Alpro Group and AstraZeneca Malaysia reaffirm their shared commitment to advancing preventive healthcare by combining greater public awareness, accessible screening and professional healthcare support.

The campaign also demonstrates the important role that community pharmacies can play in supporting wider public health efforts by providing Malaysians with convenient access to health education, early screening opportunities and trusted professional guidance within their communities.

Members of the public are encouraged to learn more about hyperkalemia by visiting www.alpropharmacy.com/pages/hyperkalemia or by speaking to an Alpro pharmacist.

References
1. KDIGO Controversies Conference. Potassium Homeostasis and Management of Dyskalemia in Kidney Diseases. Kidney International (2020). [kdigo.org]

2. National Kidney Foundation. High Potassium (Hyperkalemia): Causes, Symptoms, and Treatment (updated 2025).
Hashtag: #AlproPharmacy #AlproGroup #AreYourKidneysOK+?

The issuer is solely responsible for the content of this announcement.

About Alpro Group

Founded in 2002, Alpro Group’s ecosystem has grown to include Alpro Pharmacy, Apotek Alpro, Alpro スギ (Sugi) Pharmacy, Alpro Physio, Alpro Clinic, Alpro Baby, Alpro OptiSaver, Alpro Audiology, Alpro Health, and Alpro Foundation. Supported by a team of more than 1,000 healthcare professionals, including doctors, pharmacists, nutritionists, dietitians, physiotherapists, optometrist and many others, Alpro serves over 5 million families in Malaysia and Indonesia through its extensive network of 500 physical outlets.

Alpro Pharmacy is the first and only community pharmacy in the region to offer product liability insurance of MYR 1 million in Malaysia and IDR 3 billion in Indonesia, ensuring the supply of genuine medications and enhancing consumer trust.

With the vision of a healthy and vibrant world, Alpro Group aims to become the No. 1 prescription pharmacy chain in Southeast Asia.

About AstraZeneca

AstraZeneca is a global, science led biopharmaceutical company focused on the discovery, development, and commercialisation of innovative medicines that transform patient outcomes. Headquartered in Cambridge, United Kingdom, the company operates in more than 100 countries and plays a significant role in advancing modern healthcare through research driven innovation and strategic partnerships worldwide.

Guided by its purpose to push the boundaries of science to deliver life changing medicines, AstraZeneca prioritises long term investment in research and development. The company’s global strategy is built on deep scientific expertise, advanced technology platforms, and precision medicine approaches, including biologics, antibody drug conjugates, and data driven drug discovery. These capabilities enable AstraZeneca to address complex diseases and unmet medical needs with increasing accuracy and effectiveness.

New executive experience center helps business and technology leaders explore secure, connected AI workflows built around real business priorities.

SINGAPORE – Media OutReach Newswire – 19 August 2026 – tridorian today announced the launch of its Gemini Enterprise Experience Center in Singapore, a new physical space designed to help enterprise leaders explore how AI can support measurable business outcomes across functions such as operations, customer service, sales, finance, and internal knowledge work.

Located in tridorian’s Singapore office, the Gemini Enterprise Experience Center is intended to move the conversation beyond one-off AI experiments and feature-led demos. Instead, the center is designed around the practical questions that many organizations are now asking: which business problems should we solve first, how can AI fit securely into our existing systems and data, and what would an enterprise-ready path from idea to implementation look like.

Powered by Gemini Enterprise, including the Gemini Enterprise App and Gemini Enterprise Agent Platform, the center showcases how enterprises can securely connect business data, support multi-step workflows, and apply governance and oversight as AI use matures across the organization. Google Cloud describes Gemini Enterprise as an end-to-end system that combines secure connectors, workflow automation, governance, and identity controls, while the Agent Platform provides the foundation to build, scale, govern, and optimize enterprise-grade agents grounded in enterprise data.

Visitors to the center are guided through business-outcome narratives tailored to their role and priorities. A customer service leader might explore how AI can help reduce handling time while improving consistency. An operations leader might examine how multi-step workflows can reduce manual overhead. A CIO or risk leader might focus on governance, visibility, data controls, and the appropriate level of human involvement required for a production setting.

The center currently includes a live demo environment, which serves as a working example of how complex orchestration can be presented as a business workflow rather than a standalone chatbot interaction. In Google’s current product language, that shift reflects a broader move from isolated AI tasks towards governed systems that can support complex, multi-step work processes.

Jimmy Jigmo, CEO of tridorian said, “Most AI demos look impressive. Very few connect to the work that actually matters. The Experience Center exists because enterprise leaders don’t need more features. They need clarity on where AI fits, what governance looks like, and how to move from experiment to outcome.”

The center also offers structured workshops that guide teams from mapping business priorities and exploring role-based use cases to planning next steps like a pilot or MVP. This practical format aligns with Google Cloud’s Singapore agenda, focusing on immediate, real-world business results.

“Organizations today are moving beyond the initial excitement of AI and are now seeking solutions that are secure, governed, and fundamentally aligned with their operational realities,” said Giri Babu Madathala, Head of SMB Partnerships, JAPAC, Google Cloud. “Security and governance are no longer optional; they are the foundation upon which effective AI must be built. tridorian’s Gemini Enterprise Experience Center addresses this by providing customers with a sophisticated, hands-on environment to move from high-level experimentation to tangible results. It allows them to experience firsthand exactly how Gemini Enterprise can be integrated into their specific, real-world business workflows to drive meaningful operational efficiency”

For Singapore enterprises, this matters because AI adoption is increasingly judged not by novelty alone but by whether it can support productivity, decision quality, operational efficiency, and governance simultaneously. Singapore’s own responsible AI guidance stresses explainability, transparency, fairness, and appropriate human oversight, while enterprise examples such as DBS show that measurable value comes from disciplined implementation rather than hype.

Evan Febrianto, CTO, tridorian added “This is a place for leadership teams to explore where AI can make a difference in their business, what the right controls look like, and how to move from experimentation to enterprise implementation with greater clarity.”
Hashtag: #tridorian #technology #business #google #AI #cloud

https://tridorian.com/
https://www.linkedin.com/company/tridorian/

The issuer is solely responsible for the content of this announcement.

About tridorian

tridorian is a Google Cloud-focused services and solutions company helping organizations modernize platforms, AI, data, and applications. As a people-centric and an outcome-focused Google Cloud Premier Partner, tridorian specializes in building secure, governed AI systems designed for production. With operations spanning eight countries and customers across 14, tridorian ensures that technology only succeeds when the people using it do.

Reach out at tridorian.com/contact to discuss your business challenges and schedule a visit to tridorian’s Gemini Enterprise Experience Center.

• allnex is the global market and technology leader for Sag Control Agent (SCA) resin, a unique technology enabling excellent appearance of Automotive OEM coatings.
• Today allnex announced to build its first SCA production facility in APAC, the largest global Automotive market.
• This investment will significantly improve regional supply resilience, reduce lead times, and enhance service for our customers based in the APAC region
• And it will support faster adaptation of the next-generation of SCA’s including high-solid, low-bake, and sustainable “green SCA” solutions.

FRANKFURT, GERMANY – Media OutReach Newswire – 18 August 2026 – allnex, a leading global manufacturer and solution provider of coating resins and additives, today announced plans to expand its manufacturing footprint in Asia-Pacific with a strategic investment in Sag Control Agent (SCA) capacity at its Rayong site in Thailand.

Scheduled to begin operations in January 2028, this new SCA capacity investment, signifies allnex’s commitment to support its customers in the world’s fastest-growing automotive coatings markets.

By bringing SCA production into the APAC region, and importantly closer to customers, allnex will strengthen supply reliability, shorten lead times, and provide greater responsiveness to evolving market needs.

SCAs are a unique and cornerstone technology of allnex’s Automotive OEM product portfolio and they define its market leadership position in this application. allnex SCA resins have superior sag control functionality, enabling exceptional appearance in premium high-gloss clearcoats. These specialty resins ensure that coating manufacturers are able to meet the ever increasing demands of car producers for performance, efficiency, and sustainability.

Since allnex invented SCA resins four decades ago, all allnex SCA production was concentrated in its Bergen op Zoom facility in The Netherlands. In the last few years, APAC has become the largest SCA market globally with strong future growth projections driven by increased car production and requirements for better appearance. By making this investment in APAC, allnex will not only provide customers with proximity of supply and greater assurance, it will also ensure to have enough capacity available in time, to meet future growth.

“This strategic capacity investment for a unique technology, is driven by our commitment to our customers and their growth ambitions in Asia-Pacific. By localizing SCA production in Thailand, we are responding directly to customer needs for greater supply security, shorter lead times, and faster access to innovation. The new facility will strengthen our ability and agility to support both global and regional customers in APAC and allows us to meet future market demand.” said Ruben Mannien, Senior Executive Vice President APAC.

The Rayong site was selected following a comprehensive evaluation of multiple locations across the region. The site offers existing infrastructure, strong technical capabilities, and strategic proximity to key automotive manufacturing hubs, including China, India, Korea, and Southeast Asia.

The investment will include dedicated reactors for the production of SCA resins for plastic automotive parts and metal car bodies.

Beyond improving supply resilience, the new facility will support allnex’s latest SCA innovations designed for next-generation clearcoat systems, including high-solid, low-bake, and more sustainable coating technologies. These solutions help customers improve productivity, reduce energy consumption, and differentiate themselves in an increasingly competitive market.

Construction is expected to be completed by the end of 2027, ensuring production readiness ahead of anticipated market growth.

Hashtag: #allnex

The issuer is solely responsible for the content of this announcement.

With 1.93 million tertiary-educated workers in roles below their qualification level, employment alone may no longer be an adequate measure of career progress.

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 18 August 2026 – Malaysia’s labour market has remained resilient, with overall unemployment falling to 2.9% in the first quarter of 2026. However, the figures may conceal a deeper challenge faced by qualified workers who may be employed without meaningfully progressing in their careers. During the same period, 1.93 million tertiary-educated workers, or 35.2%, were employed in semi-skilled or low-skilled roles.

This points to a gap between employment and career progression, particularly whether the workers’ qualifications and experience are helping them move into more skilled, complex and higher-values roles.

“We need to shift the conversation from employability to career mobility. Being employed is not the same as progressing,” said Lim Bee Ing, Centre Director of The University of Manchester South East Asia Centre. “For experienced professionals in Malaysia, progression increasingly requires the ability to lead across functions, make strategic decisions and navigate change. Purposeful postgraduate education can help build those capabilities.”

Evidence across Manchester’s MBA programmes also points to rising cross-field mobility rather than individual employment factors like qualification alone. Its latest MBA employment report found that 59% of the 2024 class changed sector, while 27% changed country, industry and job function.

Experience alone does not guarantee progress

For working professionals, career mobility depends on more than time spent in a role. Both workplace experience and postgraduate education can support progression when they help build broader capabilities, prepare professionals for more complex work and lead to greater responsibility.

Experience builds capability when professionals encounter new problems, assume higher responsibilities and make increasingly complex decisions. Years spent performing largely the same scope of work, however, may not translate into equivalent professional growth.

Similarly, a Master’s can support progression when it is linked to a clear career transition, such as moving from a specialist to a managerial role, changing functions or industries, taking on regional responsibilities, or leading digital and organisational transformation. It is less likely to deliver meaningful results when pursued as a standalone credential or with the expectation of an automatic promotion or salary increase.

“For experienced professionals, the value of an MBA is not simply in acquiring more knowledge, but in seeing their experience through a broader business lens,” said Xavier Duran, Global MBA Programme Director at Alliance Manchester Business School. “That broader perspective can help prepare them for the next stage of their career, whether that means moving into leadership, changing function or industry, or even taking on greater international responsibility.”

Preparing professionals for changing employer needs

Employer expectations are also evolving. Communication, problem-solving and strategic thinking remain important, while organisations increasingly require professionals who can interpret data, understand technology and navigate the impact of artificial intelligence.

As these demands reshape the workplace, an individual can remain technically qualified and continuously employed while becoming less prepared for their next role.

Studying while working can help bridge this gap by allowing professionals to apply new concepts directly to live organisational challenges. It also enables them to examine their experience critically and connect their existing expertise with wider areas such as strategy, finance, people and technology.

The Manchester Global Part-time MBA follows this model through flexible learning, interactive workshops and practical business projects for experienced professionals. Their applicants enter with an average of 12 years of professional experience, including six years in management, underscoring that the programme is designed to build on established careers rather than replace workplace experience.

Postgraduate education is not for salary increase alone

Career progression should be looked at beyond just salary benchmarking. More meaningful indicators include movement into higher-skilled work, broader decision-making responsibility, access to regional or international opportunities and the ability to lead more complex projects.

Malaysia has made progress in helping graduates enter and remain in the workforce. The next priority should be to turn employment into sustained progression, ensuring that talent continues to develop and move into work that makes fuller use of its capabilities.

More information on the MA in Educational Leadership in Practice (ELiP) is available at www.manchester.com.my/ma-educational-leadership-in-practice/.

Hashtag: #UniversityofManchester

http://www.manchester.com.my/ma-educational-leadership-in-practice/

The issuer is solely responsible for the content of this announcement.

About The University of Manchester & Alliance Manchester Business School

The University of Manchester is ranked 35th in the world by QS World University Rankings 2026, 5th in the UK research powerhouse in REF 2021 and 2nd in THE Impact ranking 2025. With as many as 26 Nobel Prize winners, the University’s academic pedigree is among the best globally.

Alliance Manchester Business School, part of the University of Manchester, is one of the UK’s leading business schools and holds triple accreditation from AMBA, AACSB and EQUIS. The university has a global alumni network and more than 60,000 graduates across 176 countries.

Driving the Thai Economy and Charting New Strategic Pathways for the Future of ASEAN

BANGKOK, THAILAND – Media OutReach Newswire – 18 August 2026 – The Joint Standing Committee on Commerce, Industry, and Banking (JSCCIB), comprising the Thai Bankers’ Association, the Board of Trade of Thailand, and the Federation of Thai Industries, in collaboration with the Ministry of Finance, the Bank of Thailand, the National Economic and Social Development Council (NESDC), and the World Bank, has announced its readiness to convene a high-level leadership conference, ‘The Bangkok Business Summit 2026,’ under the theme ‘Reinvent Thailand, Resilient ASEAN.’

To be held at the Queen Sirikit National Convention Center (QSNCC), the summit will showcase the vision of public-private sector collaboration aimed at restructuring Thailand’s economy. This event serves as a milestone paving the way toward the IMF-World Bank Group Annual Meetings 2026, which Thailand will proudly host in Bangkok in October 2026, as well as Thailand’s upcoming ASEAN Chairmanship in 2028.

A key highlight of The Bangkok Business Summit 2026 includes a keynote address entitled ‘Thailand’s Offer to the World’ by Mr. Anutin Charnvirakul, Prime Minister of Thailand. The address will declare Thailand’s readiness as a global investment hub, shifting the nation from cost-based competition to enhancing capabilities, innovation, and digital infrastructure. Furthermore, Dr. Ekniti Nitithanprapas, Deputy Prime Minister and Minister of Finance, will deliver a policy address on ‘Unlocking the Next Growth Engines for Thailand & ASEAN,’ revealing policy reform steps designed to unlock private sector investment and drive the country’s new economic engines. Professor Dr. Yodchanan Wongsawat, Deputy Prime Minister and Minister of Higher Education, Science, Research and Innovation, will address positioning Thailand as a regional investment platform for high-tech industries.

Mr. Payong Srivanich, Chairman of the Joint Standing Committee on Commerce, Industry, and Banking (JSCCIB), stated that this event aims to answer a critical question: How can Thailand transform global shifts and its central location in ASEAN into new opportunities for investment, job creation, and sustainable growth?

“The Bangkok Business Summit 2026 is not merely a platform for exchanging perspectives, but a venue where Thailand presents its concrete strengths, opportunities, and development directions to the global business community—bridging the government’s vision, recommendations from international organizations, and the practical expertise of the private sector,” Mr. Payong stated.”Thailand’s challenge today is not just growth, but building competitive growth in a rapidly changing world. We need a platform for collaborative efforts to ‘Reinvent Thailand’ by creating new economic engines and elevating our competitiveness so Thailand can capture new opportunities and become an integral part of a ‘Resilient ASEAN’ capable of adapting to global dynamics.”

Key Highlights & Session Overview

• Special Keynote: Mr. Vitai Ratanakorn, Governor of the Bank of Thailand, will present on ‘Thailand’s New Horizons: From Ambition to Delivery.’
• Global Insights Panel: Featuring in-depth discussions with Mr. Carlos Felipe Jaramillo, World Bank Vice President for East Asia and Pacific, Mr. Sarvesh Suri, Regional Vice President for Asia and Pacific, The International Finance Corporation (IFC), and Mr. John W.H. Denton, Secretary General of the International Chamber of Commerce (ICC) exchanging views on economic trends, investments, and business opportunities.
• Report Launch: Launch of the World Bank’s latest report, ‘Building Thailand’s Future Today: The Investment and Growth Playbook.’ The report proposes a roadmap for Thailand to achieve high-income country status through investment and reforms that create jobs, boost productivity, and lay the foundation for long-term growth, highlighting potential industries such as advanced manufacturing, sustainable & wellness tourism, digital services, agriculture & food, and the creative economy.
• Luncheon Discussion: Thai Beverage Public Company Limited will host a special session entitled ‘Growth Reaches Communities: Sufficiency Economy Philosophy,’ presenting the Sufficiency Economy Philosophy as a framework that creates balance, strength, and sustainability from local communities to the business sector and macroeconomy.

Afternoon Tracks

• Track 1: Building Resilience (Infrastructure, Energy, and Digital Finance): Led by Mr. Piti Disyatat, Deputy Governor for Monetary Stability, Bank of Thailand, in building competitiveness and the ability to attract future industries to the country. The session will include discussions on the topics of ‘Efficient Energy & Low-Carbon Infrastructure’ and ‘Policy Architecture and Low-Carbon Cities in Action’ focusing on investing in key infrastructure that will drive the industrial transition to a low-carbon society, with leaders from various sectors, including the Ministry of Energy, the Ministry of Natural Resources and Environment, PTT Public Company Limited, Gulf Energy Development Public Company Limited, Siam Cement Public Company Limited, Thai Airways Public Company Limited, and Google LLC and the topic of ‘Building Thailand’s Trusted Economy: Digital Public Infrastructure for Inclusive Growth,’ focusing on digital public infrastructure in the financial sector for sustainable growth, and safe and inclusive digital finance, with senior executives from Bangkok Bank, Krungsri Bank, TMBThanachart Bank, and Ascend Money.
• Track 2: New Horizons (Future Industries, Agri-Food, and Human-Centric Economy): Led by Professor Dr. Yodchanan Wongsawat, Deputy Prime Minister and Minister of Higher Education, Science, Research and Innovation, focusing on developing high-potential talent within organizations and positioning Thailand as a regional investment platform for high-tech industries, semiconductors, AI infrastructure, and advanced R&D.

Additionally, the Bangkok Business Summit 2026 will feature a panel discussion titled ‘The Future of Agrifood Business.’ Under the concept of Elevating to a Regional Strategic Asset, leaders from top companies including Sea Value PCL and Olam Agri (Singapore) will share their perspectives on how Thailand’s agrifood industry is evolving beyond its traditional role as the ‘Kitchen of the World’ to become a vital strategic asset for regional food security, and another discussion on ‘The Future of the Human-Centric Economy,’ integrating health, wellness, tourism, and the creative economy centered around people rather than isolated sectors. Panelists include Minor International, Bangkok Dusit Medical Services (BDMS), and Cerecin.

Closing & Actions

To conclude the summit, leaders from the three JSCCIB member organizations will summarize actionable proposals to transform insights into concrete practices. These encompass enhancing competitiveness, building investment ecosystems, and developing future industries. The event will culminate in the signing of a Letter of Intent for Cooperation on the Digital & AI Compact between Thailand’s economic agencies and the World Bank.

Note: Speakers and the event program are subject to change without prior notice due to unforeseen circumstances. We apologize for any inconvenience and appreciate your understanding.
Hashtag: #JSCCIB

The issuer is solely responsible for the content of this announcement.

Partnering for better care: Mount Elizabeth Royal Square day surgery centre becomes the first IHH Healthcare facility to join Prudential’s PRUPanel Connect network

SINGAPORE– Media OutReach Newswire – 17 August 2026 – Mount Elizabeth Royal Square, a private day surgery centre, has been added to Prudential Singapore’s (“Prudential”) PRUPanel Connect panel network with effect from 1 August 2026. The empanelment was commemorated at a signing ceremony between Parkway Hospitals Singapore Pte. Ltd. and Prudential.

PRUShield Integrated Shield plan policyholders with eligible PRUExtra riders can now seek treatment at Mount Elizabeth Royal Square where they will have access to participating specialists and enjoy panel benefits.

Mount Elizabeth Royal Square is the first facility under IHH Healthcare Singapore to be included in the PRUPanel Connect network.

Dr Peter Chow, Chief Executive Officer, IHH Healthcare Singapore, said: “We are pleased to partner Prudential to bring Mount Elizabeth Royal Square into the PRUPanel Connect network. This collaboration reflects our shared commitment to improving access to quality private healthcare, while giving eligible patients greater assurance and convenience when they require day surgery or endoscopy care.”

Chan San San, Chief Executive Officer, Prudential Singapore, said: “At Prudential, we want to make it easier for customers to navigate their healthcare journey with confidence. By adding Mount Elizabeth Royal Square to PRUPanel Connect, we are strengthening our panel ecosystem and giving PRUShield Extra customers more options for specialist day surgery care, supported by the benefits and assurance of our panel network.”

Opened in 2025, Mount Elizabeth Royal Square is a day surgery and endoscopy centre offering hospital-equivalent safety standards, shorter waiting times, dedicated procedure slots, and a seamless patient experience. The centre also provides bedside ultrasound services, a dedicated patient lounge, and is conveniently located right next to Mount Elizabeth Novena Hospital.

Through PRUPanel Connect, eligible Prudential customers have access to value-added services when they seek treatment with participating specialists at panel healthcare institutions. These services are available to customers holding eligible PRUExtra policies, including PRUExtra Premier Care, PRUExtra Preferred Care, PRUExtra Premier, PRUExtra Premier CoPay and PRUExtra Preferred CoPay. Customers may enjoy benefits such as cashless admission with an electronic Letter of Guarantee of up to S$15,000, subject to eligibility, as well as keep renewable premiums stable for panel-approved claims.

Notes:

• PRUPanel Connect – PRUPanel Connect | Prudential Singapore
• PRUShield – PRUShield – Health Insurance Plan | Prudential Singapore

Hashtag: #PrudentialSingapore

https://www.prudential.com.sg/
https://www.linkedin.com/company/prudential-assurance-company-singapore
https://www.facebook.com/PrudentialSingapore/
https://www.instagram.com/prudentialsingapore/

The issuer is solely responsible for the content of this announcement.

About IHH Healthcare Singapore

IHH Healthcare Singapore (IHH SG) is part of IHH Healthcare, a world leader in integrated care with a presence in 10 markets across the world. As Singapore’s largest private healthcare provider, IHH SG operates an integrated network of four multi-award-winning acute hospitals – Gleneagles Hospital, Mount Elizabeth Hospital, Mount Elizabeth Novena Hospital and Parkway East Hospital – where more than 1,800 accredited specialists provide quality multi-disciplinary specialist care.

IHH SG’s network extends beyond acute and tertiary care to primary, specialty care and ancillary services. Its Parkway brand includes the Parkway Shenton network of over 50 clinics island-wide, and iXchange, its managed care and employee benefits arm. Together with Parkway Cancer Centre, Parkway MediCentre, Parkway Radiology, Parkway Laboratories, Parkway Rehab and Parkway Emergency Services, IHH SG’s comprehensive range of services underpins its position as the country’s most trusted healthcare provider, known for providing quality medical care and clinical outcomes in Singapore and around the region.

For more information, visit https://www.ihhhealthcare.com/singapore/.

About Prudential Assurance Company Singapore (Pte) Ltd (Prudential Singapore)

Prudential Assurance Company Singapore (Pte) Ltd is one of the top life and health insurance companies in Singapore, serving the financial and protection needs of the country’s citizens for 95 years. As at 31 December 2025, it has S$66.3 billion funds under management. The company has an ‘AA’ Financial Strength Rating from leading credit rating agency Standard & Poor’s and delivers a suite of well-rounded product offerings in Protection, Savings and Investment through multiple distribution channels including a network of 5,400 financial representatives.

For more information, visit https://www.prudential.com.sg

Approximately 800 Cambodian leaders and Church members gathered Wednesday morning on the temple grounds, located at Russian Confederation Street Phnom Penh 12040 on a 1.3-hectare site.

Represented at the event were top leaders in government, diplomatic corps, religion, business, education, health care and the news media.

They heard speeches from Church leaders and His Excellency Minister Chay Borin of the Ministry of Cult and Religion, who represented His Excellency Prime Minister Hun Manet.

Leading the Church delegation was Elder Gerrit W. Gong, a member of the Quorum of the Twelve Apostles and senior leader from Church headquarters in Salt Lake City, Utah.

The commemoration will continue with public open house tours:

• Saturdays, 15 & 22 August: 9:00 a.m.–7:00 p.m.
• Monday–Friday, 17–21 August: 4:00 p.m.–8:00 p.m.
• Sunday, 16 August: No tours available.

Tours are free with no reservation required. More information is available at:
https://www.churchofjesuschrist.org/featured/phnom-penh-cambodia-open-house?lang=khm.

In his speech, Minister Chay Borin said he was “honored and delighted” to represent Prime Minister Hun Manet at the event. He noted the “magnificent architecture and craftsmanship” of the Phnom Penh Temple and said it demonstrates the growth of religious faith in Cambodia. It is also a reflection of the peace, political stability and freedom of religious belief enjoyed by Cambodian citizens.

Elder Gong said, “For us, this temple is a holy and sacred place where heaven and earth come together in serenity and harmony. In the temple, we worship God and receive His blessings. We learn God’s plan of happiness and our divine identity and purpose. We promise and covenant to live good, moral, productive, faith-filled lives.”

Regarding the temple, Minister Borin told the large group of government and community leaders, “I firmly believe that this new holy place will become a place where love and peace are nurtured, a place where people can leave behind wrongdoing and sin, and a place that contributes to cultivating morality, virtue, and good conduct among all those who come here to worship.”

The temple is a “symbol of peace and of building strong and harmonious families for generations to come, consistent with one of the Church’s core teachings, which emphasizes strong and enduring families as an important foundation of society.”

Elder Gong said he and his wife love visiting Cambodia and have met with Church members and friends all across the country. Cambodia, he said, “is a miracle of modern development” while also preserving Khmer history and culture. “We are grateful for the privilege to worship freely in this beautiful country in meetinghouses and places of worship,” he said.

Elder Gong said Church members “believe we are all children of God, which makes us brothers and sisters. As such, we are grateful to work with the government of Cambodia to provide hundreds of humanitarian, education, and medical projects to benefit our Cambodian brothers and sisters regardless of religion.”

Elder Gong noted that Cambodia is a country that treasures temples. “Temples are also special to us,” he said. “We are grateful for the permitting and support we have received to build this temple in Phnom Penh.”

Sacred temple ceremonies bless God’s children, said Elder Gong, both those who are living and those who have passed on to the next life. “Temple ceremonies encourage our members – from the young to the elderly – to love and honor deceased family members. Parents, grandparents, and ancestors can be united with their families, happy and forever. Temple ceremonies bless families and individuals with peace, healing, forgiveness, and unity.”

Cambodian Church member Vichit Ith, who was instrumental in obtaining official government recognition of the Church in 1994 so it could begin operating, also spoke at the event.

“Today, our Church family in Cambodia has grown to over 20,000 members,” he said, “worshipping in chapels across the nation—each one a testament to the faith, devotion, and resilience of our Cambodian brothers and sisters.”

Brother Ith said the temple is “a monument to the enduring friendship and mutual respect between our Church and the Kingdom of Cambodia.”

In the temple, said Brother Ith, “members commit to follow God and, in turn, become more upright and reliable citizens. It is a place of eternal families – where marriages are sealed not ‘until death do us part,’ but for eternity, strengthening the social fabric of Cambodia one family at a time. It is also a place of divine knowledge – where members learn about God’s plan for humanity, giving them hope, purpose, and a desire to serve others.”

Following the public open house, the temple will be formally dedicated on Sunday, 30 August 2026. After the dedication, the temple grounds will remain open to visitors, but entry into the temple itself will be reserved for faithful members of the Church.

Hashtag: #PhnomPenhTemple #CambodiaTemple #TempleOpenHouse #ComeAndSee #StrongerFamilies #PeaceAndHarmony #Cambodia #PhnomPenh

https://news-kh.churchofjesuschrist.org/
https://www.facebook.com/ChurchofJesusChrist.kh

The issuer is solely responsible for the content of this announcement.

Veteran insurance leader to accelerate growth, strengthen partnerships and drive customer-focused innovation

SINGAPORE – Media OutReach Newswire – 14 August 2026 – Etiqa Insurance Singapore today announced the official appointment of Claudia Soh as its Chief Executive Officer (CEO), effective 14 Aug 2026. Over the past six months, while serving as Acting Chief Executive Officer and continuing in her role as Chief Financial Officer, Claudia has led Etiqa Insurance Singapore through a period of sustained growth and transformation, strengthening the company’s foundations while driving initiatives focused on innovation, operational excellence, and customer-centricity. Her appointment reflects the Board’s confidence in her leadership and vision as the company embarks on its next phase of growth.

With more than 20 years of experience in the financial services and insurance industry, Claudia brings extensive expertise across finance, strategic planning, risk management, mergers and acquisitions, investor relations and auditing. Her career spans both the public and private sectors, including experience at the Monetary Authority of Singapore (MAS) and senior leadership roles within the insurance industry.

During her tenure at Etiqa, Claudia has helped build on the company’s strong momentum by supporting its growth agenda while advancing new initiatives. Her collaborative leadership approach and focus on long-term value creation have contributed to strengthening Etiqa’s capabilities for the future. She has also been an advocate for transforming the finance function from a traditional support role into a strategic business partner that helps create stronger outcomes for customers, employees and stakeholders.

“We are delighted to formally appoint Claudia Soh as CEO of Etiqa Insurance Singapore,” said Kamaludin, Group Chief Executive Officer, Etiqa Insurance and Takaful. “Claudia has demonstrated strong leadership, strategic clarity, operational excellence and resilience. Her ability to drive innovation, build strong teams and adapt to changing customer needs will continue to strengthen our market position in Singapore to deliver long-tern value for our customers, employees and stakeholders”

On her appointment, Claudia said, “I am honoured to undertake the role of CEO at Etiqa Insurance Singapore at a time of significant change for our industry. As customer expectations continue to evolve, we must remain agile, innovative and focused on delivering purposeful value. By combining digital innovation, data-driven insights and strong partnerships, we will continue to enhance the customer experience and help more individuals and businesses build financial confidence and resilience.”

Deepening Partnerships and Empowering Financial Readiness

As a leading composite insurer, Etiqa Insurance Singapore will continue to deepen its distribution capabilities and ecosystem partnerships to make protection more accessible and relevant to customers. Beyond its longstanding bancassurance partnership, Etiqa will work closely with Maybank to deliver more integrated financial and protection solutions, leveraging the strength of the Maybank network and customer ecosystem. Etiqa will also continue collaborating with partners across Singapore to develop innovative solutions that support customers’ evolving protection, savings and financial wellness needs.
Hashtag: #EtiqaInsuranceSingapore

https://www.etiqa.com.sg/

The issuer is solely responsible for the content of this announcement.

About Etiqa Insurance Pte. Ltd. (Etiqa Insurance Singapore)

Protecting customers since 1961, Etiqa Insurance Pte. Ltd. (EIPL) is a life and general insurance company licensed and regulated by the Monetary Authority of Singapore and governed by the Insurance Act 1966. Having protected customers in Singapore since 1961 under the name United General Insurance Co. Sdn. Bhd., the company transitioned into the Singapore branch of Etiqa Insurance Berhad in 2009. Today, EIPL in Singapore stands as the pivotal operating entity of Etiqa Insurance Group, a leading insurance and takaful provider in ASEAN.

EIPL offers a comprehensive range of life and general insurance products accessible through its diverse distribution channels, including bancassurance, agents, brokers, financial advisers, partnerships, direct and online sales via Tiq by Etiqa. Etiqa is rated ‘A’ by credit rating agency Fitch for the group’s ‘Favorable’ business profile. The company is a member of the Maybank Group.

2Q26 Business and Financial Highlights

• Bora delivered historically record-high quarterly revenues of NT$5,889 million in 2Q26, up 47.2% quarter-over-quarter driven by broad-based operational momentum, with basic EPS of NT$4.36.
• CDMO revenue growth and increased site utilization rates, along with strong growth in the rare disease business and a return to growth for generics business of the Pharma Sales operations lifted group profitability, with gross margin expanding to 41.3% from 36.0% and operating margin reaching 16.8% from 10.2% in 1Q26. Excluding one-time costs related to the Weider Global Nutrition transaction, operating margin was approximately 18%.
• CDMO’s strong backlog of US$317 million as of end of 2Q26, another historical high following a strong quarter, signals that Bora’s core business continued to perform with higher demand.
• Pharma Sales’ rare disease franchise continues to show double digit sequential growth and the increased demand from government channels during the quarter with stabilized pricing in DLS has lifted the generics business back to normal.
• Reflecting Bora’s recent increase in investment in Sunway Biotech, from 35.97% to 42.27% and subsequent acquisitions of Weider Global Nutrition’s, the Company has introduced “Consumer Healthcare (CHC)” as a new segment in its revenue mix disclosure beginning this quarter. In 2Q26, revenues from CHC were NT$824.76 million in 2Q26, a 354.4% increase QoQ and 234.3% YoY, and contributed to 14% of the Bora Groups consolidated revenues, an all-time high.
• Cash-on-hand reached an all-time high of NT$8,431 million as the Company was preparing for MacroGenics Inc.’s Rockville facility acquisition.
• The Company has kicked off a group-wide AI in Manufacturing, BORA AIM, program aimed at improving process efficiency across sites, spanning engineering, quality and production. Bora has also signed a partnership with Insilico Medicine for AI drug discovery. The first 6 months will focus on beta version testing of the Bora AIM agents and AI champions to drive process consolidation.
• Share capital increased 0.3% during the quarter from employee stock option exercise.

Mr. Bobby Sheng, Chairman of Bora Group, stated, “We are pleased to announce Bora Group’s return to strong operating profits and double to triple-digit growth on all key margins sequentially, as well as demonstrate that our soft 1Q26 performance was anomalous rather than structural. Our impressive sequential improvement was driven entirely by strong demand from both our CDMO and Pharma Sales businesses, with 2Q26 manufactured batches reaching 0.38 billion doses, led by increased commercial production in Maple Grove and Zhunan sites and a full quarter of operations in the Maryland injectable facility, while our flagship products DLS and VIGAFYDE® in Pharma Sales continues to secure leading market share.

Our focus right now is execution. CAPEX investments in our mature sites, including facilities in Taiwan and in Canada, continue to deliver operational leverage driven by gross margin expansion, and our recently acquired oral solid dose facility in Maple Grove continues to show stellar and impactful demand as we sign more projects. Our 12-month rolling backlog is at historic high in almost all our sites, despite projected manufacturing delays at our Maryland injectable facility as we diligently respond to FDA audit observations from a recent audit. Bora Group’s commitment to the fast-growing Biologics manufacturing industry took another big step as we look to integrate 12,000 liters of capacity, and 3 commercial products from our Rockville facility, as well as see revenue recognition from this acquisition starting Q3. As Bora’s CDMO footprint expands in the US, we continue to capture durable, high-value demand as customers increasingly prioritize supply security and onshore capacity.

In addition, we are seeing sustained growth and improved gross margins in the Vigabatrin franchise, our most important, rare disease franchise, thanks to renegotiations with our partner vendors. Accelerated state and government orders for generics products increased 2Q26 revenues and 6 new generics launches have also supported a more diversified generics portfolio. Together, the advancement in rare disease franchise and generics business has positioned Bora’s Pharma Sales business, operating under the name Upsher-Smith, in a far stronger state than it was just a quarter ago.

As announced in July, we are excited to be developing a group-wide AI in Manufacturing program, BORA AIM, aimed at improving process efficiency across sites, spanning engineering, quality and production. We also announced a partnership with Insilico Medicine to enhance our understanding of AI drug discovery and create more customized AI manufacturing platforms for AIDD small molecules. In the next 12 months, Bora Group will be ready to showcase some exciting AI-enabled CDMO platforms that will truly add value to our partners and sharpen the overall competitive advantages of Bora Group.

As our momentum carries Bora into the second half of the year, we expect margins of our flagship products in Pharma Sales and CHC businesses to hold steady on continuous revenue growth, and improved efficiencies in the CDMO business in addition to consolidation of new revenues from the Rockville facility.”

2Q26 Operational Achievements & 2026 Outlook

Global CDMO Operations

Revenues increased 30.3% year-over-year and 29.0% quarter-over-quarter including internal orders, and 33.0% and 40.2% external orders only, or NT$2,116.4 million. The growth was primarily driven by a strong rebound in injectables following the semi-annual maintenance in 1Q26 and same period last year, and demand acceleration overall as we continue to meet the increasing backlog.

CDMO business also signed a record high US$378.2 million in total external wins. Highlighted by a 10+2-year, multi product commercial contract in our Maple Grove facility with a new top-20 pharma company, and 14 new molecules from pre-commercial programs from multiple new customers. Bora is confident in its mid- to long-term growth trajectory as pharma and biotech companies continue to look for US based CDMOs as a part of their efforts to onshore US production and improve supply chain resilience.

During the quarter, 0.38 billion doses, or 109 molecules, were developed and manufactured. Contribution from the top 20 global pharmaceutical companies stood at roughly 30% and should increase drastically in the next 8 quarters.

Looking at 3Q26, the Company is highly optimistic, with our backlog having climbed to an unprecedented level even after a strong quarter of manufacturing output. We do anticipate some timing shifts in revenue recognition related to scheduled semi-annual maintenance at our Maryland injectable site, alongside targeted quality-enhancement activities in connection with observations on passive RABS (Restricted Access Barrier System) line received from an FDA audit that took place 2Q26. However, there has been no reduction in total commercial batch productions in 2026 as we speak and several existing clients have initiated transfers to the FlexPro isolator filling lines. RFP activity has risen, with the first GMP PPQ campaign starting in August. On the newest, isolator-based AST lines, factory acceptance testing (FAT) is planned for Q326, with qualification to follow in 2027, expanding our ability to onboard small-scale isolator programs, including tech transfers.

On biologics, Rockville facility revenue recognition started in the first month of 3Q26 and the site has confirmed that it is on track to deliver batch production volumes ahead of last year’s run rate of around 13 batches for the remainder of 2026. We anticipate one-time transaction costs from this acquisition of approximately 3% of the purchase price including legal and FA fee and transition related expenses as stated in the Transition Service Agreement. The Rockville acquisition expands biologics capacity and brings integrated drug substance (DS) and drug product (DP) capabilities under one roof, strengthening our end-to-end service offering and attracting more inbound opportunities and higher value conversion with cross selling opportunities for our injectable business.

For our strategic investment in Tanvex Biopharma, the main Bora Biologics platform company, although the business still operates at a loss, Tanvex has built a strong presence in international conferences, especially Bio International in the US in June. We have seen a positive uptick in pipeline from leading biotechs and heavy weight biopharmas, and stable demand for early-stage PD programs in Zhubei. The Rockville acquisition is expected to orchestrate and accelerate opportunities for Tanvex in the coming quarters.

Pharma Sales Operations

Revenues decreased 2.7% year-over-year and increased 30.4% quarter-over-quarter, arriving at NT$2,934.04 million in 2Q26. The year-over-year decrease was mainly due to a product rationalization program in 2025 that lead to the withdrawal of a basket of legacy generics products.

During the quarter, specialty and brand came in strongly, up 58.8% for the quarter QoQ and displayed almost 50% growth against 2025 run rate. The rare-disease Vigabatrin franchise demand is robust, and our continuous investment in the segment has resulted in much broader patient access compared to when we acquired Upsher-Smith 28 months ago. On coverage, we are on track to achieve year-end formulary goal of >50%, supported by more regional plans and strong physician adoption as they gain experience with VIGAFYDE®. The Company has also renegotiated contracts with suppliers, leading to improved gross margins for the franchise during the quarter and expects full economic contribution starting 3Q26. Simultaneously, the Company out-licensed its non-core assets, Stiripentol generics and 505(b)(2), during the quarter, fully capturing the economic value of these drug assets to enable fueled and renewed focus on core specialty and brand business.

The generics business returned to stability as Upsher-Smith successfully defended flagship product DLS. High value generics advanced 20.6% sequentially from downstream restocking, narrowing the year-to-date YoY decline against 2025 run rate to high teens.

Having executed our way through specialty and brand business growth and generics portfolio optimization, we have returned to the 2023–2024 peaks of Pharma Sales performance but with healthier and more resilient operating profits. As of now, Upsher-Smith sees 6 ANDA pending approval.

CHC Operations

Bora Group has increased holdings of Sunway Biotech to 42.27% through a private placement at $NT 596 million. Subsequently, Sunway completed the acquisition of Weider Global Nutrition (WGN), a global nutritional supplements company with offices in the US, Spain, and Germany and products sold in over 60 countries. Benefitting from the consolidation of WGN that started in May, Consumer Health business totaled NT$824.76 million in 2Q26, a 354.4% increase QoQ and 234.3% YoY. Focusing on longevity and sports nutrition, WGN’s distribution strength is expected to meaningfully contribute to the CHC business in 2026 and beyond and shall deliver vertical-integration synergies to Sunway’s existing ingredients’ manufacturing operations. Together, the WGN acquisition is expected to catapult Sunway Biotech into a leading global nutritional supplements company and substantially accelerate top and bottom-line improvements in the future.

Recent Investor Conference

Bora will host English online earnings call at 8:00 a.m. Taiwan time on Aug. 14^th, 2026. The event will cover the Company’s 2Q26 financial and business results and 2H26 outlook.

English Online Earnings Presentation Link: https://teams.microsoft.com/meet/225504163505748?p=UyyncWl1CnOzjBCNKD

Bora will participate in Goldman Sachs 2026 CDMO day in Singapore in Sept. For 1:1 meetings with management, please contact your GS representative.

Bora 2026 Earnings Schedule

Q3 2026: Expected in the 2^nd week of Nov 2026
Q4 2026: Expected in the 2^nd week of Mar 2027

Hashtag: #BoraGroup

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.